Business

Haemonetics Announces CE Mark Certification for VASCADE MVP XL Vascular Closure System

· GlobeWire Daily Business Desk · Source: www.prnewswire.com

2 min read

Key takeawaysHaemonetics Corporation has announced that its VASCADE MVP® XL venous vascular closure system has received CE Mark certification under the European Medical Device Regulation (EU-MDR). This regulatory milestone allows the medical technology company to expand its commercial footprint for larger-bore venous closure into the European Union and other regions…
Haemonetics Announces CE Mark Certification for VASCADE MVP XL Vascular Closure System

Original GlobeWire Daily editorial illustration — not an event photograph.

Haemonetics Corporation has announced that its VASCADE MVP® XL venous vascular closure system has received CE Mark certification under the European Medical Device Regulation (EU-MDR). This regulatory milestone allows the medical technology company to expand its commercial footprint for larger-bore venous closure into the European Union and other regions recognizing the CE mark.

Following the certification, the first European clinical procedures utilizing the VASCADE MVP XL system were completed in October 2026. These initial cases were performed by Prof. Christian H. Heeger at Asklepios Clinic Altona in Hamburg, Germany; Prof. Claudio Tondo at Centro Cardiologico Monzino, IRCCS, in Milan, Italy; and Dr. Riyaz A. Kaba at Cromwell Hospital in London, UK.

Clinical Applications and Design Features

The VASCADE MVP XL system is indicated for the percutaneous closure of femoral venous access sites following catheter-based procedures utilizing 10–12F inner diameter procedural sheaths (up to a 15F maximum outer diameter), such as cryoablation, Pulsed Field Ablation (PFA), and Left Atrial Appendage Closure (LAAC). According to company details, the device aims to provide:

  • Reduced time to ambulation and hemostasis
  • Shorter total post-procedure time and time to discharge eligibility
  • Facilitation of same-day discharge for eligible patients
  • Integration of 58% more collagen and a 9% larger disc compared to the standard VASCADE MVP system

Portfolio Context and Verification

The VASCADE MVP XL joins Haemonetics' broader vascular closure portfolio, which includes the original VASCADE system for small-bore procedures and the VASCADE MVP system for mid-bore multi-access femoral venous closure. Both devices feature collapsible disc technology and a resorbable collagen plug.

Readers and stakeholders looking to verify the original regulatory announcement or review ongoing corporate updates can consult the Investor Relations section of the official Haemonetics website at www.haemonetics.com, or review official filings with the U.S. Securities and Exchange Commission.

Share this article
Read the original source: Haemonetics Announces CE Mark Certification for the VASCADE MVP® XL Venous Vascular Closure System

AI-assisted reporting; source claims are attributed and have not been independently verified.

About the author

GlobeWire Daily Business Desk — AI-assisted news based on attributed published sources.

More to read